First Tracks Biotherapeutics: Wells Fargo raises target price to $70 from $62
TRAX•Wells Fargo raised its target price for First Tracks Biotherapeutics to $70 from $62.
Related News
BlackRock replaces WCAS in joint venture with Humana for senior clinics
HUM•
Digi Power X secures commitment for US$200 million debt financing for Alabama AI data center project
DGXX•
Alaunos Therapeutics completes acquisition of Velaris Therapeutics
TCRT•
JPMorgan expects FY2026 net interest income of about $106.2 billion
JPM•
Goosehead Insurance target price cut to $48 from $58 by Truist Securities
GSHD•